To clarify, MAPS is required to run 2 x 100-person phase 3 trials. Interim analysis confirmed they didn't need to enroll more than 100 people for that first trial (and due to COVID, FDA offered to end early with only 90 subjects). Another phase 3 trial (MAPP2) of 100 people is still needed, so unfortunately there are no savings on time or money.
To clarify, MAPS is required to run 2 x 100-person phase 3 trials. Interim analysis confirmed they didn't need to enroll more than 100 people for that first trial (and due to COVID, FDA offered to end early with only 90 subjects). Another phase 3 trial (MAPP2) of 100 people is still needed, so unfortunately there are no savings on time or money.
Well there goes my whole hypothesis. Thanks Michael
Is the pump&dump image for Champignon, nee Apotheosis? I also couldn't find the infor for Silo Wellness, but did see that this just happened https://www.globenewswire.com/news-release/2020/06/17/2049450/0/en/Yukoterre-Resources-Announces-Proposed-Reverse-Takeover-by-Psychdelics-Company-Silo-Wellness.html
Wow - how is that for timing. Not a peep for months and then this, thanks for sharing.